Lv11
70 积分 2024-04-16 加入
Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis
2小时前
待确认
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
2小时前
已完结
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia
12天前
已完结
FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study
19天前
已完结
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials
20天前
已完结
Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years’ real-world experience in a single institute
29天前
已完结
Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension
3个月前
已完结
Avatrombopag for the treatment of immune thrombocytopenia
3个月前
已完结
ViPOR’s Venom — Rationally Targeting DLBCL with Precision
5个月前
已完结
Diffuse Large B-Cell Lymphoma
5个月前
已完结
皖公网安备34019202002308
